The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics Inc. warns that inadequate tumor penetration remains a significant barrier in treating many solid tumors, notably in HPV negative recurrent and metastatic head and neck squamous cell carcinoma (R M HNSCC).
These tumors often develop fibrotic and immunosuppressive environments, leading to elevated EGFR expression, increased TGF beta 1 production, and high rates of resistance to standard therapies. The company is focused on advancing understanding and potential solutions to improve penetration and overcome therapeutic obstacles in these challenging cancer types.
These latest efforts by Bicara Therapeutics build on the company’s sustained focus on both overcoming scientific barriers and fostering enduring patient trust—a theme highlighted in recent discussions of its commitment to patient engagement and community advocacy. Meanwhile, strategic financial moves such as the recent oversubscribed equity offering to fund ficerafusp alfa advancement further illustrate the multifaceted approach Bicara is taking to address therapeutic and operational challenges in oncology.